Early signals support target-directed treatment, including cMET blockade that radiosensitizes NF2 schwannoma models, brigatinib-associated tumor shrinkage in NF2-deficient models, and PitNET organoid data.<h4>Conclusions</h4>We support clinical decision-making that utilizes molecular profiling with functional testing to guide targeted treatment. This evidence concerns the gene NF2 and schwannoma.